SECURITIES
AND EXCHANGE COMMISSION


WASHINGTON,
D.C. 20549




AMENDMENT
NO. 1 TO


FORM
10-QSB


ON
FORM 10-Q/A




x QUARTERLY REPORT
      UNDER SECTION 13 OR 15(d) OF THE SECURITIES ACT OF
  1934





For the
quarterly period ended March 31, 2008





o TRANSITION REPORT
      UNDER SECTION 13 OR 15(d) OF THE SECURITIES ACT OF
  1934





For the
transition period from _______________ to _________________




Commission
file number: 000-32253





HUIFENG
BIO-PHARMACEUTICAL TECHNOLOGY, INC.


(Name of
Small Business Issuer as specific in its Charter)





Nevada
            
            87-0650264(State
      or Other Jurisdiction of
              Incorporation
      or Organization)
            
            (I.R.S.
      Employer Identification No.)




16B/F
Ruixin Bldg. No. 25 Gaoxin Road


Xi’an
710075 Shaanxi Province, China


(Address
of Principal Executive Offices Including Zip Code)




Check
whether the issuer (1) filed all reports required to be filed by Section 13 or
15(d) of the Exchange Act during the past 12 months (or for such shorter period
that the registrant was required to file such reports), and (2) has been subject
to such filing requirements for the past 90 days.x Yeso No





The
number of shares outstanding of the registrant's common equity as of March 31,
2008, was 18,466,169 shares of common stock, par value $0.018.





Transitional
Small Business Disclosure Format (Check one):o Yesx No









EXLANATORY
NOTE




This
Amendment No. 1 to Form 10-QSB on Form 10-Q(the “Amended Filing”) amends the
quarterly report on Form 10-QSB for the quarter ended March 31, 2008, originally
filed on May 20, 2008 (the “Original Filing”), of Huifeng Bio-Pharmaceutical
Technology, Inc., a Nevada corporation (“HFGB” or the “Company”). The purpose of
this amendment is to revise (1) Part I, Item 3. Controls and Procedures, and (2)
the Principal Executive Officer and Principal Financial Officer certifications
as required by Item 601(b)(31) of Regulation S-K.




In
accordance with Rule 12b-15 under the Exchange Act, each item of the Original
Filing that is amended by this Amended Filing is also restated in its entirety,
and this Amended Filing is accompanied by currently dated certifications on
Exhibits 31.1, 31.2, 32.1 and 32.2 by the Company’s Chief Executive Officer and
Chief Financial Officer. Except as described above, this Amended Filing does not
amend, update, or change any items, financial statements, or other disclosures
in the Original Filing, and does not reflect events occurring after the filing
of the Original Filing, including as to any exhibits to the Original Filing
affected by subsequent events. Information not affected by the changes described
above is unchanged and reflects the disclosures made at the time of the Original
Filing. Accordingly, this Amended Filing should be read in conjunction with the
Original Filing and our other SEC filings subsequent to the filing of the
Original Filing, including any amendments to those filings. Capitalized terms
not defined in the Amended Filing are as defined by the Original
Filing.





PART
I





Item
3. Controls and Procedures




We
maintain disclosure controls and procedures that are designed to ensure that
information required to be disclosed in the Company's Exchange Act reports is
recorded, processed, summarized and reported within the time periods specified
in the SEC's rules and forms, and that such information is accumulated and
communicated to our management, including its Chief Executive Officer and Chief
Financial Officer, as appropriate, to allow timely decisions regarding required
disclosure based closely on the definition of "disclosure controls and
procedures" in 13a-15(e) and 15d-15(e) under the Securities Exchange Act of
1934, as amended, as of the end of the period covered by this quarterly report
on From 10-Q (the “Evaluation Date”). Our disclosure controls and procedures are
designed to provide a reasonable level of assurance of reaching our desired
disclosure control objectives. In designing and evaluating the disclosure
controls and procedures, our management recognized that any controls and
procedures, no matter how well designed and operated, can provide only
reasonable assurance of achieving the desired control objectives, and management
necessarily was required to apply its judgment in evaluating the cost-benefit
relationship of possible controls and procedures. Our certifying officers have
concluded that our disclosure controls and procedures require additional
diligence to be considered effective in reaching that level of
assurance.




As of the
Evaluation Date, we carried out an evaluation, under the supervision and with
the participation of our management including our Chief Executive Officer and
our Chief Financial Officer, of the effectiveness of the design and operation of
our disclosure controls and procedures. Based on the foregoing, our Chief
Executive Officer and Chief Financial Officer concluded that with the additional
controls and procedures we have put in place, our disclosure controls and
procedures were effective as of the Evaluation Date.




PART
II. OTHER INFORMATION





Item 6. Exhibits





(a)
Exhibits





31.1
            Sarbanes
      Oxley Section 302 Certification31.2
            Sarbanes
      Oxley Section 302 Certification32.1
            Sarbanes
      Oxley Section 906 Certification32.2
            Sarbanes
      Oxley Section 906 Certification








SIGNATURES





Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of
1934, as amended, the registrant has duly caused this Report to be signed on its
behalf by the undersigned, thereunto duly authorized this 20th day of January,
2009.






HUIFENG
      BIO-PHARMACEUTICAL TECHNOLOGY, INCBy:
              /s/
      Jing’an WangJing’an
      WangChief
      Executive Officer